Neuropeptide regulation of stress-induced behavior: Insights from the CRF/urocortin family

Handbook of Neuroendocrinology

Volumn , Issue , 2012, Pages 355-375

  Sztainberg, Yehezkel ^a   Chen, Alon ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861195921     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-375097-6.10015-0     Document Type: Chapter

References (264)

1. Vale W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 1981, 213:1394-1397.
2. Rivier C., Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature. 1983, 305:325-327.
3. Muglia L., Jacobson L., Dikkes P., Majzoub J.A. Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. Nature. 1995, 373:427-432.
4. Sutton R.E., Koob G.F., Le Moal M., Rivier J., Vale W. Corticotropin releasing factor produces behavioural activation in rats. Nature. 1982, 297:331-333.
5. Koob G.F., Heinrichs S.C. A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res. 1999, 848:141-152.
6. Brown M.R., Fisher L.A., Spiess J., Rivier C., Rivier J., Vale W. Corticotropin-releasing factor: actions on the sympathetic nervous system and metabolism. Endocrinology. 1982, 111:928-931.
7. de Kloet E.R., Joels M., Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci. 2005, 6:463-475.
8. Chrousos G.P., Gold P.W. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. J Am Med Assoc. 1992, 267:1244-1252.
9. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res. 1999, 33:181-214.
10. Holmes A., Heilig M., Rupniak N.M., Steckler T., Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci. 2003, 24:580-588.
11. Vaughan J., Donaldson C., Bittencourt J., Perrin M.H., Lewis K., Sutton S., Chan R., Turnbull A.V., Lovejoy D., Rivier C., et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature. 1995, 378:287-292.
12. Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A., Hogenesch J.B., Gulyas J., Rivier J., Vale W.W., Sawchenko P.E. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA. 2001, 98:2843-2848.
13. Hsu S.Y., Hsueh A.J. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med. 2001, 7:605-611.
14. Lewis K., Li C., Perrin M.H., Blount A., Kunitake K., Donaldson C., Vaughan J., Reyes T.M., Gulyas J., Fischer W., Bilezikjian L., Rivier J., Sawchenko P.E., Vale W.W. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA. 2001, 98:7570-7575.
15. Chen R., Lewis K.A., Perrin M.H., Vale W.W. Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci USA. 1993, 90:8967-8971.
16. Vita N., Laurent P., Lefort S., Chalon P., Lelias J.M., Kaghad M., Le Fur G., Caput D., Ferrara P. Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Lett. 1993, 335:1-5.
17. Chang C.P., Pearse R.V., O'Connell S., Rosenfeld M.G. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron. 1993, 11:1187-1195.
18. Perrin M., Donaldson C., Chen R., Blount A., Berggren T., Bilezikjian L., Sawchenko P., Vale W. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci USA. 1995, 92:2969-2973.
19. Stenzel P., Kesterson R., Yeung W., Cone R.D., Rittenberg M.B., Stenzel-Poore M.P. Identification of a novel murine receptor for corticotropin-releasing hormone expressed in the heart. Mol Endocrinol. 1995, 9:637-645.
20. Kishimoto T., Pearse R.V., Lin C.R., Rosenfeld M.G. A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci USA. 1995, 92:1108-1112.
21. Lovenberg T.W., Liaw C.W., Grigoriadis D.E., Clevenger W., Chalmers D.T., De Souza E.B., Oltersdorf T. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA. 1995, 92:836-840.
22. Chen A., Perrin M., Brar B., Li C., Jamieson P., Digruccio M., Lewis K., Vale W. Mouse corticotropin-releasing factor receptor type 2alpha gene: isolation, distribution, pharmacological characterization and regulation by stress and glucocorticoids. Mol Endocrinol. 2005, 19:441-458.
23. Pisarchik A., Slominski A. Molecular and functional characterization of novel CRFR1 isoforms from the skin. Eur J Biochem. 2004, 271:2821-2830.
24. Grammatopoulos D.K., Dai Y., Randeva H.S., Levine M.A., Karteris E., Easton A.J., Hillhouse E.W. A novel spliced variant of the type 1 corticotropin-releasing hormone receptor with a deletion in the seventh transmembrane domain present in the human pregnant term myometrium and fetal membranes. Mol Endocrinol. 1999, 13:2189-2202.
25. Van Pett K., Viau V., Bittencourt J.C., Chan R.K., Li H.Y., Arias C., Prins G.S., Perrin M., Vale W., Sawchenko P.E. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol. 2000, 428:191-212.
26. Kostich W.A., Chen A., Sperle K., Largent B.L. Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol Endocrinol. 1998, 12:1077-1085.
27. Lovenberg T.W., Chalmers D.T., Liu C., De Souza E.B. CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology. 1995, 136:4139-4142.
28. Potter E., Behan D.P., Fischer W.H., Linton E.A., Lowry P.J., Vale W.W. Cloning and characterization of the cDNAs for human and rat corticotropin releasing factor-binding proteins. Nature. 1991, 349:423-426.
29. Behan D.P., De Souza E.B., Lowry P.J., Potter E., Sawchenko P., Vale W.W. Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides. Front Neuroendocrinol. 1995, 16:362-382.
30. Seasholtz A.F., Valverde R.A., Denver R.J. Corticotropin-releasing hormone-binding protein: biochemistry and function from fishes to mammals. J Endocrinol. 2002, 175:89-97.
31. Dunn A.J., Berridge C.W. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?. Brain Res Brain Res Rev. 1990, 15:71-100.
32. Steckler T., Holsboer F. Corticotropin-releasing hormone receptor subtypes and emotion. Biol Psychiatry. 1999, 46:1480-1508.
33. Heinrichs S.C., Koob G.F. Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. J Pharmacol Exp Ther. 2004, 311:427-440.
34. Zorrilla EP, Koob GF. Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today 15, 371-83.
35. Lowry C.A., Moore F.L. Regulation of behavioral responses by corticotropin-releasing factor. Gen Comp Endocrinol. 2006, 146:19-27.
36. Dunn A.J., Berridge C.W., Lai Y.I., Yachabach T.L. CRF-induced excessive grooming behavior in rats and mice. Peptides. 1987, 8:841-844.
37. Sherman J.E., Kalin N.H. The effects of ICV-CRH on novelty-induced behavior. Pharmacol Biochem Behav. 1987, 26:699-703.
38. Jones D.N., Kortekaas R., Slade P.D., Middlemiss D.N., Hagan J.J. The behavioural effects of corticotropin-releasing factor-related peptides in rats. Psychopharmacology (Berl). 1998, 138:124-132.
39. Eaves M., Thatcher-Britton K., Rivier J., Vale W., Koob G.F. Effects of corticotropin releasing factor on locomotor activity in hypophysectomized rats. Peptides. 1985, 6:923-926.
40. Britton D.R., Varela M., Garcia A., Rosenthal M. Dexamethasone suppresses pituitary-adrenal but not behavioral effects of centrally administered CRF. Life Sci. 1986, 38:211-216.
41. Moore F.L., Miller L.J. Stress-induced inhibition of sexual behavior: corticosterone inhibits courtship behaviors of a male amphibian (Taricha granulosa). Horm Behav. 1984, 18:400-410.
42. Lowry C.A., Deviche P., Moore F.L. Effects of corticotropin-releasing factor (CRF) and opiates on amphibian locomotion. Brain Res. 1990, 513:94-100.
43. Lowry C.A., Burke K.A., Renner K.J., Moore F.L., Orchinik M. Rapid changes in monoamine levels following administration of corticotropin-releasing factor or corticosterone are localized in the dorsomedial hypothalamus. Horm Behav. 2001, 39:195-205.
44. Lowry C.A., Moore F.L. Corticotropin-releasing factor (CRF) antagonist suppresses stress-induced locomotor activity in an amphibian. Horm Behav. 1991, 25:84-96.
45. Clements S., Schreck C.B., Larsen D.A., DickhoffW.W. Central administration of corticotropin-releasing hormone stimulates locomotor activity in juvenile chinook salmon (Oncorhynchus tshawytscha). Gen Comp Endocrinol. 2002, 125:319-327.
46. Clements S., Schreck C.B. Central administration of corticotropin-releasing hormone alters downstream movement in an artificial stream in juvenile chinook salmon (Oncorhynchus tshawytscha). Gen Comp Endocrinol. 2004, 137:1-8.
47. Ohgushi A., Bungo T., Shimojo M., Masuda Y., Denbow D.M., Furuse M. Relationships between feeding and locomotion behaviors after central administration of CRF in chicks. Physiol Behav. 2001, 72:287-289.
48. Zhang R., Nakanishi T., Ohgushi A., Ando R., Yoshimatsu T., Denbow D.M., Furuse M. Interaction of corticotropin-releasing factor and glucagon-like peptide-1 on behaviors in chicks. Eur J Pharmacol. 2001, 430:73-78.
49. Johnson R.W., von Borell E.H., Anderson L.L., Kojic L.D., Cunnick J.E. Intracerebroventricular injection of corticotropin-releasing hormone in the pig: acute effects on behavior, adrenocorticotropin secretion, and immune suppression. Endocrinology. 1994, 135:642-648.
50. Salak-Johnson J.L., McGlone J.J., Whisnant C.S., Norman R.L., Kraeling R.R. Intracerebroventricular porcine corticotropin-releasing hormone and cortisol effects on pig immune measures and behavior. Physiol Behav. 1997, 61:15-23.
51. Parrott R.F., Vellucci S.V., Goode J.A. Behavioral and hormonal effects of centrally injected "anxiogenic" neuropeptides in growing pigs. Pharmacol Biochem Behav. 2000, 65:123-129.
52. Parrott R.F., Vellucci S.V. Behaviour of pigs given corticotrophin-releasing hormone in combination with flumazenil or diazepam. Pharmacol Biochem Behav. 2000, 67:465-471.
53. Berridge C.W., Dunn A.J. Corticotropin-releasing factor elicits naloxone sensitive stress-like alterations in exploratory behavior in mice. Regul Pept. 1986, 16:83-93.
54. Dunn A.J., Berridge C.W. Corticotropin-releasing factor administration elicits a stress-like activation of cerebral catecholaminergic systems. Pharmacol Biochem Behav. 1987, 27:685-691.
55. Kalin N.H., Shelton S.E., Kraemer G.W., McKinney W.T. Corticotropin-releasing factor administered intraventricularly to rhesus monkeys. Peptides. 1983, 4:217-220.
56. Winslow J.T., Newman J.D., Insel T.R. CRH and alpha-helical-CRH modulate behavioral measures of arousal in monkeys. Pharmacol Biochem Behav. 1989, 32:919-926.
57. Takahashi L.K., Kalin N.H., Vanden Burgt J.A., Sherman J.E. Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats. Behav Neurosci. 1989, 103:648-654.
58. Baldwin H.A., Rassnick S., Rivier J., Koob G.F., Britton K.T. CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology (Berl). 1991, 103:227-232.
59. Momose K., Inui A., Asakawa A., Ueno N., Nakajima M., Fujimiya M., Kasuga M. Intracerebroventricularly administered corticotropin-releasing factor inhibits food intake and produces anxiety-like behaviour at very low doses in mice. Diabetes Obes Metab. 1999, 1:281-284.
60. Berridge C.W., Dunn A.J. CRF and restraint-stress decrease exploratory behavior in hypophysectomized mice. Pharmacol Biochem Behav. 1989, 34:517-519.
61. Spadaro F., Berridge C.W., Baldwin H.A., Dunn A.J. Corticotropin-releasing factor acts via a third ventricle site to reduce exploratory behavior in rats. Pharmacol Biochem Behav. 1990, 36:305-309.
62. Sherman J.E., Kalin N.H. ICV-CRH alters stress-induced freezing behavior without affecting pain sensitivity. Pharmacol Biochem Behav. 1988, 30:801-807.
63. Pelleymounter M.A., Joppa M., Carmouche M., Cullen M.J., Brown B., Murphy B., Grigoriadis D.E., Ling N., Foster A.C. Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF. J Pharmacol Exp Ther. 2000, 293:799-806.
64. Dunn A.J., File S.E. Corticotropin-releasing factor has an anxiogenic action in the social interaction test. Horm Behav. 1987, 21:193-202.
65. Swerdlow N.R., Geyer M.A., Vale W.W., Koob G.F. Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology (Berl). 1986, 88:147-152.
66. Liang K.C., Melia K.R., Miserendino M.J., Falls W.A., Campeau S., Davis M. Corticotropin-releasing factor: long-lasting facilitation of the acoustic startle reflex. J Neurosci. 1992, 12:2303-2312.
67. Diamant M., Croiset G., de Wied D. The effect of corticotropin-releasing factor (CRF) on autonomic and behavioral responses during shock-prod burying test in rats. Peptides. 1992, 13:1149-1158.
68. Arase K., York D.A., Shimizu H., Shargill N., Bray G.A. Effects of corticotropin-releasing factor on food intake and brown adipose tissue thermogenesis in rats. Am J Physiol. 1988, 255:E255-E259.
69. Krahn D.D., Gosnell B.A., Grace M., Levine A.S. CRF antagonist partially reverses CRF- and stress-induced effects on feeding. Brain Res Bull. 1986, 17:285-289.
70. Gosnell B.A., Morley J.E., Levine A.S. A comparison of the effects of corticotropin releasing factor and sauvagine on food intake. Pharmacol Biochem Behav. 1983, 19:771-775.
71. Benoit S.C., Thiele T.E., Heinrichs S.C., Rushing P.A., Blake K.A., Steeley R.J. Comparison of central administration of corticotropin-releasing hormone and urocortin on food intake, conditioned taste aversion, and c-Fos expression. Peptides. 2000, 21:345-351.
72. Pedersen C.A., Caldwell J.D., McGuire M., Evans D.L. Corticotropin-releasing hormone inhibits maternal behavior and induces pup-killing. Life Sci. 1991, 48:1537-1546.
73. Sirinathsinghji D.J. Inhibitory influence of corticotropin releasing factor on components of sexual behaviour in the male rat. Brain Res. 1987, 407:185-190.
74. Cador M., Ahmed S.H., Koob G.F., Le Moal M., Stinus L. Corticotropin-releasing factor induces a place aversion independent of its neuroendocrine role. Brain Res. 1992, 597:304-309.
75. Heinrichs S.C., Britton K.T., Koob G.F. Both conditioned taste preference and aversion induced by corticotropin-releasing factor. Pharmacol Biochem Behav. 1991, 40:717-721.
76. Moreau J.L., Kilpatrick G., Jenck F. Urocortin, a novel neuropeptide with anxiogenic-like properties. NeuroReport. 1997, 8:1697-1701.
77. Spina M.G., Merlo-Pich E., Akwa Y., Balducci C., Basso A.M., Zorrilla E.P., Britton K.T., Rivier J., Vale W.W., Koob G.F. Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat. Psychopharmacology (Berl). 2002, 160:113-121.
78. Regev L, Ezrielev E, Gershon E, Gil S, Chen A Genetic approach for intracerebroventricular delivery. Proc Natl Acad Sci USA. 2010, 107:4424-4429.
79. LeDoux J. The amygdala. Curr Biol. 2007, 17:R868-R874.
80. Ehrlich I., Humeau Y., Grenier F., Ciocchi S., Herry C., Luthi A. Amygdala inhibitory circuits and the control of fear memory. Neuron. 2009, 62:757-771.
81. Roozendaal B., McEwen B.S., Chattarji S. Stress, memory and the amygdala. Nat Rev Neurosci. 2009, 10:423-433.
82. Palkovits M., Brownstein M.J., Vale W. Distribution of corticotropin-releasing factor in rat brain. Fed Proc. 1985, 44:215-219.
83. Swanson L.W., Sawchenko P.E., Rivier J., Vale W.W. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology. 1983, 36:165-186.
84. De Souza E.B., Insel T.R., Perrin M.H., Rivier J., Vale W.W., Kuhar M.J. Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study. J Neurosci. 1985, 5:3189-3203.
85. Justice N.J., Yuan Z.F., Sawchenko P.E., Vale W. Type 1 corticotropin-releasing factor receptor expression reported in BAC transgenic mice: implications for reconciling ligand-receptor mismatch in the central corticotropin-releasing factor system. J Comp Neurol. 2008, 511:479-496.
86. Tazi A., Swerdlow N.R., LeMoal M., Rivier J., Vale W., Koob G.F. Behavioral activation by CRF: evidence for the involvement of the ventral forebrain. Life Sci. 1987, 41:41-49.
87. Wiersma A., Bohus B., Koolhaas J.M. Corticotropin-releasing hormone microinfusion in the central amygdala diminishes a cardiac parasympathetic outflow under stress-free conditions. Brain Res. 1993, 625:219-227.
88. Liang K.C., Lee E.H. Intra-amygdala injections of corticotropin releasing factor facilitate inhibitory avoidance learning and reduce exploratory behavior in rats. Psychopharmacology (Berl). 1988, 96:232-236.
89. Sajdyk T.J., Schober D.A., Gehlert D.R., Shekhar A. Role of corticotropin-releasing factor and urocortin within the basolateral amygdala of rats in anxiety and panic responses. Behav Brain Res. 1999, 100:207-215.
90. Spiga F., Lightman S.L., Shekhar A., Lowry C.A. Injections of urocortin 1 into the basolateral amygdala induce anxiety-like behavior and c-Fos expression in brainstem serotonergic neurons. Neuroscience. 2006, 138:1265-1276.
91. Rainnie D.G., Bergeron R., Sajdyk T.J., Patil M., Gehlert D.R., Shekhar A. Corticotrophin releasing factor-induced synaptic plasticity in the amygdala translates stress into emotional disorders. J Neurosci. 2004, 24:3471-3479.
92. Jochman K.A., Newman S.M., Kalin N.H., Bakshi V.P. Corticotropin-releasing factor-1 receptors in the basolateral amygdala mediate stress-induced anorexia. Behav Neurosci. 2005, 119:1448-1458.
93. Keen-Rhinehart E., Michopoulos V., Toufexis D.J., Martin E.I., Nair H., Ressler K.J., Davis M., Owens M.J., NemeroffC.B., Wilson M.E. Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes. Mol Psychiatry. 2009, 14:37-50.
94. Regev L., Neufeld-Cohen A., Tsoory M., Kuperman Y., Getselter D., Gil S., Chen A. Prolonged and site-specific overexpression of corticotropin-releasing factor reveals differential roles for extended amygdala nuclei in emotional regulation. Mol Psychiatry 2011, in press.
95. Heinrichs S.C., Pich E.M., Miczek K.A., Britton K.T., Koob G.F. Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res. 1992, 581:190-197.
96. Swiergiel A.H., Takahashi L.K., Kalin N.H. Attenuation of stress-induced behavior by antagonism of corticotropin-releasing factor receptors in the central amygdala in the rat. Brain Res. 1993, 623:229-234.
97. Liebsch G., Landgraf R., Gerstberger R., Probst J.C., Wotjak C.T., Engelmann M., Holsboer F., Montkowski A. Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul Pept. 1995, 59:229-239.
98. Sajdyk T.J., Gehlert D.R. Astressin, a corticotropin releasing factor antagonist, reverses the anxiogenic effects of urocortin when administered into the basolateral amygdala. Brain Res. 2000, 877:226-234.
99. Robison C.L., MeyerhoffJ.L., Saviolakis G.A., Chen W.K., Rice K.C., Lumley L.A. A CRH1 antagonist into the amygdala of mice prevents defeat-induced defensive behavior. Ann NY Acad Sci. 2004, 1032:324-327.
100. Sztainberg Y, Kuperman Y, Tsoory M, Lebow M, Chen A The anxiolytic effect of environmental enrichment is mediated via amygdalar CRF receptor type 1. Mol Psychiatry. 2010, 15:905-917.
101. Walker D.L., Toufexis D.J., Davis M. Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur J Pharmacol. 2003, 463:199-216.
102. Chalmers D.T., Lovenberg T.W., De Souza E.B. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci. 1995, 15:6340-6350.
103. Walker D.L., Miles L.A., Davis M. Selective participation of the bed nucleus of the stria terminalis and CRF in sustained anxiety-like versus phasic fear-like responses. Prog Neuropsychopharmacol Biol Psychiatry. 2009, 33:1291-1308.
104. Lee Y., Davis M. Role of the hippocampus, the bed nucleus of the stria terminalis, and the amygdala in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex. J Neurosci. 1997, 17:6434-6446.
105. Lee Y., Fitz S., Johnson P.L., Shekhar A. Repeated stimulation of CRF receptors in the BNST of rats selectively induces social but not panic-like anxiety. Neuropsychopharmacology. 2008, 33:2586-2594.
106. Sahuque L.L., Kullberg E.F., McGeehan A.J., Kinder J.R., Hicks M.P., Blanton M.G., Janak P.H., Olive M.F. Anxiogenic and aversive effects of corticotropin-releasing factor (CRF) in the bed nucleus of the stria terminalis in the rat: role of CRF receptor subtypes. Psychopharmacology (Berl). 2006, 186:122-132.
107. Liang K.C., Chen H.C., Chen D.Y. Posttraining infusion of norepinephrine and corticotropin releasing factor into the bed nucleus of the stria terminalis enhanced retention in an inhibitory avoidance task. Chin J Physiol. 2001, 44:33-43.
108. Ciccocioppo R., Fedeli A., Economidou D., Policani F., Weiss F., Massi M. The bed nucleus is a neuroanatomical substrate for the anorectic effect of corticotropin-releasing factor and for its reversal by nociceptin/orphanin FQ. J Neurosci. 2003, 23:9445-9451.
109. Silverman A.J., Hou-Yu A., Chen W.P. Corticotropin-releasing factor synapses within the paraventricular nucleus of the hypothalamus. Neuroendocrinology. 1989, 49:291-299.
110. Gray T.S., Magnuson D.J. Peptide immunoreactive neurons in the amygdala and the bed nucleus of the stria terminalis project to the midbrain central gray in the rat. Peptides. 1992, 13:451-460.
111. Monnikes H., Heymann-Monnikes I., Tache Y. CRF in the paraventricular nucleus of the hypothalamus induces dose-related behavioral profile in rats. Brain Res. 1992, 574:70-76.
112. Krahn D.D., Gosnell B.A., Levine A.S., Morley J.E. Behavioral effects of corticotropin-releasing factor: localization and characterization of central effects. Brain Res. 1988, 443:63-69.
113. Heinrichs S.C., Menzaghi F., Pich E.M., Hauger R.L., Koob G.F. Corticotropin-releasing factor in the paraventricular nucleus modulates feeding induced by neuropeptide Y. Brain Res. 1993, 611:18-24.
114. Elliott E., Ezra-Nevo G., Regev L., Neufeld-Cohen A., Chen A. Resilience to social stress coincides with functional DNA methylation of the Crf gene in adult mice. Nat Neurosci. 2010, 13:1351-1353.
115. Phillips R.G., LeDoux J.E. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci. 1992, 106:274-285.
116. Maren S., Aharonov G., Fanselow M.S. Neurotoxic lesions of the dorsal hippocampus and Pavlovian fear conditioning in rats. Behav Brain Res. 1997, 88:261-274.
117. Radulovic J., Ruhmann A., Liepold T., Spiess J. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci. 1999, 19:5016-5025.
118. Todorovic C., Radulovic J., Jahn O., Radulovic M., Sherrin T., Hippel C., Spiess J. Differential activation of CRF receptor subtypes removes stress-induced memory deficit and anxiety. Eur J Neurosci. 2007, 25:3385-3397.
119. Bertoglio L.J., Joca S.R., Guimaraes F.S. Further evidence that anxiety and memory are regionally dissociated within the hippocampus. Behav Brain Res. 2006, 175:183-188.
120. Pentkowski N.S., Blanchard D.C., Lever C., Litvin Y., Blanchard R.J. Effects of lesions to the dorsal and ventral hippocampus on defensive behaviors in rats. Eur J Neurosci. 2006, 23:2185-2196.
121. Pentkowski N.S., Litvin Y., Blanchard D.C., Vasconcellos A., King L.B., Blanchard R.J. Effects of acidic-astressin and ovine-CRF microinfusions into the ventral hippocampus on defensive behaviors in rats. Horm Behav. 2009, 56:35-43.
122. Cassens G., Roffman M., Kuruc A., Orsulak P.J., Schildkraut J.J. Alterations in brain norepinephrine metabolism induced by environmental stimuli previously paired with inescapable shock. Science. 1980, 209:1138-1140.
123. Korf J., Aghajanian G.K., Roth R.H. Increased turnover of norepinephrine in the rat cerebral cortex during stress: role of the locus coeruleus. Neuropharmacology. 1973, 12:933-938.
124. Cedarbaum J.M., Aghajanian G.K. Activation of locus coeruleus neurons by peripheral stimuli: modulation by a collateral inhibitory mechanism. Life Sci. 1978, 23:1383-1392.
125. Grzanna R., Molliver M.E. The locus coeruleus in the rat: an immunohistochemical delineation. Neuroscience. 1980, 5:21-40.
126. Swanson L.W. The locus coeruleus: a cytoarchitectonic, Golgi and immunohistochemical study in the albino rat. Brain Res. 1976, 110:39-56.
127. Swanson L.W., Hartman B.K. The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker. J Comp Neurol. 1975, 163:467-505.
128. Butler P.D., Weiss J.M., Stout J.C., NemeroffC.B. Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. J Neurosci. 1990, 10:176-183.
129. Swiergiel A.H., Takahashi L.K., Rubin W.W., Kalin N.H. Antagonism of corticotropin-releasing factor receptors in the locus coeruleus attenuates shock-induced freezing in rats. Brain Res. 1992, 587:263-268.
130. Smagin G.N., Harris R.B., Ryan D.H. Corticotropin-releasing factor receptor antagonist infused into the locus coeruleus attenuates immobilization stress-induced defensive withdrawal in rats. Neurosci Lett. 1996, 220:167-170.
131. Chen M.F., Chiu T.H., Lee E.H. Noradrenergic mediation of the memory-enhancing effect of corticotropin-releasing factor in the locus coeruleus of rats. Psychoneuroendocrinology. 1992, 17:113-124.
132. Fekete E.M., Zorrilla E.P. Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol. 2007, 28:1-27.
133. Kuperman Y., Chen A. Urocortins: emerging metabolic and energy homeostasis perspectives. Trends Endocrinol Metab. 2008, 19:122-129.
134. Joels M., Baram T.Z. The neuro-symphony of stress. Nat Rev Neurosci. 2009, 10:459-466.
135. NemeroffC.B. The role of corticotropin-releasing factor in the pathogenesis of major depression. Pharmacopsychiatry. 1988, 21:76-82.
136. NemeroffC.B. New vistas in neuropeptide research in neuropsychiatry: focus on corticotropin-releasing factor. Neuropsychopharmacology. 1992, 6:69-75.
137. Arborelius L., Owens M.J., Plotsky P.M., NemeroffC.B. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol. 1999, 160:1-12.
138. Reul J.M., Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol. 2002, 2:23-33.
139. Valdez G.R., Inoue K., Koob G.F., Rivier J., Vale W., Zorrilla E.P. Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res. 2002, 943:142-150.
140. Valdez G.R., Zorrilla E.P., Rivier J., Vale W.W., Koob G.F. Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist. Brain Res. 2003, 980:206-212.
141. Henry B., Vale W., Markou A. The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J Neurosci. 2006, 26:9142-9152.
142. Zhao Y., Valdez G.R., Fekete E.M., Rivier J.E., Vale W.W., Rice K.C., Weiss F., Zorrilla E.P. Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats. J Pharmacol Exp Ther. 2007, 323:846-854.
143. Heinrichs S.C., Lapsansky J., Lovenberg T.W., De Souza E.B., Chalmers D.T. Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul Pept. 1997, 71:15-21.
144. Liebsch G., Landgraf R., Engelmann M., Lorscher P., Holsboer F. Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. J Psychiatr Res. 1999, 33:153-163.
145. Ruhmann A., Bonk I., Lin C.R., Rosenfeld M.G., Spiess J. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc Natl Acad Sci USA. 1998, 95:15264-15269.
146. Takahashi L.K., Ho S.P., Livanov V., Graciani N., Arneric S.P. Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety. Brain Res. 2001, 902:135-142.
147. Ohata H., Shibasaki T. Effects of urocortin 2 and 3 on motor activity and food intake in rats. Peptides. 2004, 25:1703-1709.
148. Zorrilla E.P., Reinhardt L.E., Valdez G.R., Inoue K., Rivier J.E., Vale W.W., Koob G.F. Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity. J Pharmacol Exp Ther. 2004, 310:1027-1034.
149. Venihaki M., Sakihara S., Subramanian S., Dikkes P., Weninger S.C., Liapakis G., Graf T., Majzoub J.A. Urocortin III, a brain neuropeptide of the corticotropin-releasing hormone family: modulation by stress and attenuation of some anxiety-like behaviours. J Neuroendocrinol. 2004, 16:411-422.
150. Bakshi V.P., Smith-Roe S., Newman S.M., Grigoriadis D.E., Kalin N.H. Reduction of stress-induced behavior by antagonism of corticotropin-releasing hormone 2 (CRH2) receptors in lateral septum or CRH1 receptors in amygdala. J Neurosci. 2002, 22:2926-2935.
151. Hammack S.E., Schmid M.J., LoPresti M.L., Der-Avakian A., Pellymounter M.A., Foster A.C., Watkins L.R., Maier S.F. Corticotropin releasing hormone type 2 receptors in the dorsal raphe nucleus mediate the behavioral consequences of uncontrollable stress. J Neurosci. 2003, 23:1019-1025.
152. Ho S.P., Takahashi L.K., Livanov V., Spencer K., Lesher T., Maciag C., Smith M.A., Rohrbach K.W., Hartig P.R., Arneric S.P. Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor. Brain Res Mol Brain Res. 2001, 89:29-40.
153. Risbrough V.B., Hauger R.L., Pelleymounter M.A., Geyer M.A. Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (Berl). 2003, 170:178-187.
154. Pelleymounter M.A., Joppa M., Ling N., Foster A.C. Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress. J Pharmacol Exp Ther. 2002, 302:145-152.
155. Pelleymounter M.A., Joppa M., Ling N., Foster A.C. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides. 2004, 25:659-666.
156. Neufeld-Cohen A, Evans AK, Getselter D, Spyroglou A, Hill A, Gil S, Tsoory M, Beuschlein F, Lowry CA, Vale W, Chen A. Urocortin-1 and -2 double-deficient mice show robust anxiolytic phenotype and modified serotonergic activity in anxiety circuits. Mol Psychiatry. 15, 426-41, 339.
157. Staub D.R., Evans A.K., Lowry C.A. Evidence supporting a role for corticotropin-releasing factor type 2 (CRF2) receptors in the regulation of subpopulations of serotonergic neurons. Brain Res. 2006, 1070:77-89.
158. Staub D.R., Spiga F., Lowry C.A. Urocortin 2 increases c-Fos expression in topographically organized subpopulations of serotonergic neurons in the rat dorsal raphe nucleus. Brain Res. 2005, 1044:176-189.
159. Amat J., Tamblyn J.P., Paul E.D., Bland S.T., Amat P., Foster A.C., Watkins L.R., Maier S.F. Microinjection of urocortin 2 into the dorsal raphe nucleus activates serotonergic neurons and increases extracellular serotonin in the basolateral amygdala. Neuroscience. 2004, 129:509-519.
160. Maier S.F., Watkins L.R. Stressor controllability and learned helplessness: the roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci Biobehav Rev. 2005, 29:829-841.
161. Bakshi V.P., Kalin N.H. Corticotropin-releasing hormone and animal
162. Bale T.L., Vale W.W. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol. 2004, 44:525-557.
163. Keck M.E., Ohl F., Holsboer F., Muller M.B. Listening to mutant mice: a spotlight on the role of CRF/CRF receptor systems in affective disorders. Neurosci Biobehav Rev. 2005, 29:867-889.
164. Stenzel-Poore M.P., Cameron V.A., Vaughan J., Sawchenko P.E., Vale W. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology. 1992, 130:3378-3386.
165. Stenzel-Poore M.P., Heinrichs S.C., Rivest S., Koob G.F., Vale W.W. Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J Neurosci. 1994, 14:2579-2584.
166. van Gaalen M.M., Stenzel-Poore M.P., Holsboer F., Steckler T. Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur J Neurosci. 2002, 15:2007-2015.
167. Heinrichs S.C., Min H., Tamraz S., Carmouche M., Boehme S.A., Vale W.W. Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated. Psychoneuroendocrinology. 1997, 22:215-224.
168. Heinrichs S.C., Stenzel-Poore M.P., Gold L.H., Battenberg E., Bloom F.E., Koob G.F., Vale W.W., Pich E.M. Learning impairment in transgenic mice with central overexpression of corticotropin-releasing factor. Neuroscience. 1996, 74:303-311.
169. van Gaalen M.M., Stenzel-Poore M., Holsboer F., Steckler T. Reduced attention in mice overproducing corticotropin-releasing hormone. Behav Brain Res. 2003, 142:69-79.
170. Dirks A., Groenink L., Bouwknecht J.A., Hijzen T.H., Van Der Gugten J., Ronken E., Verbeek J.S., Veening J.G., Dederen P.J., Korosi A., Schoolderman L.F., Roubos E.W., Olivier B. Overexpression of corticotropin-releasing hormone in transgenic mice and chronic stress-like autonomic and physiological alterations. Eur J Neurosci. 2002, 16:1751-1760.
171. Dirks A., Groenink L., Schipholt M.I., van der Gugten J., Hijzen T.H., Geyer M.A., Olivier B. Reduced startle reactivity and plasticity in transgenic mice overexpressing corticotropin-releasing hormone. Biol Psychiatry. 2002, 51:583-590.
172. Kasahara M., Groenink L., Breuer M., Olivier B., Sarnyai Z. Altered behavioural adaptation in mice with neural corticotrophin-releasing factor overexpression. Genes Brain Behav. 2007, 6:598-607.
173. Lu A., Steiner M.A., Whittle N., Vogl A.M., Walser S.M., Ableitner M., Refojo D., Ekker M., Rubenstein J.L., Stalla G.K., Singewald N., Holsboer F., Wotjak C.T., Wurst W., Deussing J.M. Conditional mouse mutants highlight mechanisms of corticotropin-releasing hormone effects on stress-coping behavior. Mol Psychiatry. 2008, 13:1028-1042.
174. Venihaki M., Majzoub J.A. Animal models of CRH deficiency. Front Neuroendocrinol. 1999, 20:122-145.
175. Dunn A.J., Swiergiel A.H. Behavioral responses to stress are intact in CRF-deficient mice. Brain Res. 1999, 845:14-20.
176. Weninger S.C., Dunn A.J., Muglia L.J., Dikkes P., Miczek K.A., Swiergiel A.H., Berridge C.W., Majzoub J.A. Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc Natl Acad Sci USA. 1999, 96:8283-8288.
177. Smith G.W., Aubry J.M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., Chen R., Marchuk Y., Hauser C., Bentley C.A., Sawchenko P.E., Koob G.F., Vale W., Lee K.F. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron. 1998, 20:1093-1102.
178. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M., Stalla G.K., Blanquet V., Steckler T., Holsboer F., Wurst W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet. 1998, 19:162-166.
179. Turnbull A.V., Smith G.W., Lee S., Vale W.W., Lee K.F., Rivier C. CRF type I receptor-deficient mice exhibit a pronounced pituitary-adrenal response to local inflammation. Endocrinology. 1999, 140:1013-1017.
180. Contarino A., Dellu F., Koob G.F., Smith G.W., Lee K.F., Vale W., Gold L.H. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res. 1999, 835:1-9.
181. Gammie S.C., Stevenson S.A. Intermale aggression in corticotropin-releasing factor receptor 1 deficient mice. Behav Brain Res. 2006, 171:63-69.
182. Gammie S.C., Bethea E.D., Stevenson S.A. Altered maternal profiles in corticotropin-releasing factor receptor 1 deficient mice. BMC Neurosci. 2007, 8:17.
183. Bale T.L., Contarino A., Smith G.W., Chan R., Gold L.H., Sawchenko P.E., Koob G.F., Vale W.W., Lee K.F. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet. 2000, 24:410-414.
184. Coste S.C., Kesterson R.A., Heldwein K.A., Stevens S.L., Heard A.D., Hollis J.H., Murray S.E., Hill J.K., Pantely G.A., Hohimer A.R., Hatton D.C., Phillips T.J., Finn D.A., Low M.J., Rittenberg M.B., Stenzel P., Stenzel-Poore M.P. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet. 2000, 24:403-409.
185. Kishimoto T., Radulovic J., Radulovic M., Lin C.R., Schrick C., Hooshmand F., Hermanson O., Rosenfeld M.G., Spiess J. Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet. 2000, 24:415-419.
186. Bale T.L., Vale W.W. Increased depression-like behaviors in corticotropin-releasing factor receptor-2-deficient mice: sexually dichotomous responses. J Neurosci. 2003, 23:5295-5301.
187. Todorovic C., Sherrin T., Pitts M., Hippel C., Rayner M., Spiess J. Suppression of the MEK/ERK signaling pathway reverses depression-like behaviors of CRF2-deficient mice. Neuropsychopharmacology. 2009, 34:1416-1426.
188. Burrows H.L., Nakajima M., Lesh J.S., Goosens K.A., Samuelson L.C., Inui A., Camper S.A., Seasholtz A.F. Excess corticotropin releasing hormone-binding protein in the hypothalamic-pituitary-adrenal axis in transgenic mice. J Clin Invest. 1998, 101:1439-1447.
189. Lovejoy D.A., Aubry J.M., Turnbull A., Sutton S., Potter E., Yehling J., Rivier C., Vale W.W. Ectopic expression of the CRF-binding protein: minor impact on HPA axis regulation but induction of sexually dimorphic weight gain. J Neuroendocrinol. 1998, 10:483-491.
190. Karolyi I.J., Burrows H.L., Ramesh T.M., Nakajima M., Lesh J.S., Seong E., Camper S.A., Seasholtz A.F. Altered anxiety and weight gain in corticotropin-releasing hormone-binding protein-deficient mice. Proc Natl Acad Sci USA. 1999, 96:11595-11600.
191. Gammie S.C., Seasholtz A.F., Stevenson S.A. Deletion of corticotropin-releasing factor binding protein selectively impairs maternal, but not intermale aggression. Neuroscience. 2008, 157:502-512.
192. Bale T.L., Picetti R., Contarino A., Koob G.F., Vale W.W., Lee K.F. Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. J Neurosci. 2002, 22:193-199.
193. Preil J., Muller M.B., Gesing A., Reul J.M., Sillaber I., van Gaalen M.M., Landgrebe J., Holsboer F., Stenzel-Poore M., Wurst W. Regulation of the hypothalamic-pituitary-adrenocortical system in mice deficient for CRH receptors 1 and 2. Endocrinology. 2001, 142:4946-4955.
194. Korte S.M., Korte-Bouws G.A., Koob G.F., De Kloet E.R., Bohus B. Mineralocorticoid and glucocorticoid receptor antagonists in animal models of anxiety. Pharmacol Biochem Behav. 1996, 54:261-267.
195. Tronche F., Kellendonk C., Kretz O., Gass P., Anlag K., Orban P.C., Bock R., Klein R., Schutz G. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet. 1999, 23:99-103.
196. Muller M.B., Zimmermann S., Sillaber I., Hagemeyer T.P., Deussing J.M., Timpl P., Kormann M.S., Droste S.K., Kuhn R., Reul J.M., Holsboer F., Wurst W. Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci. 2003, 6:1100-1107.
197. Vetter D.E., Li C., Zhao L., Contarino A., Liberman M.C., Smith G.W., Marchuk Y., Koob G.F., Heinemann S.F., Vale W., Lee K.F. Urocortin-deficient mice show hearing impairment and increased anxiety-like behavior. Nat Genet. 2002, 31:363-369.
198. Wang X., Su H., Copenhagen L.D., Vaishnav S., Pieri F., Shope C.D., Brownell W.E., De Biasi M., Paylor R., Bradley A. Urocortin-deficient mice display normal stress-induced anxiety behavior and autonomic control but an impaired acoustic startle response. Mol Cell Biol. 2002, 22:6605-6610.
199. Chen A., Zorrilla E., Smith S., Rousso D., Levy C., Vaughan J., Donaldson C., Roberts A., Lee K.F., Vale W. Urocortin 2-deficient mice exhibit gender-specific alterations in circadian hypothalamus-pituitary-adrenal axis and depressive-like behavior. J Neurosci. 2006, 26:5500-5510.
200. Li C., Chen P., Vaughan J., Lee K.F., Vale W. Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis. Proc Natl Acad Sci USA. 2007, 104:4206-4211.
201. Deussing JM, Breu J, Kuhne C, Kallnik M, Bunck M, Glasl L, Yen YC, Schmidt MV, Zurmuhlen R, Vogl AM, Gailus-Durner V, Fuchs H, Holter SM, Wotjak CT, Landgraf R, de Angelis MH, Holsboer F, Wurst W. Urocortin 3 modulates social discrimination abilities via corticotropin-releasing hormone receptor type 2. J Neurosci. 30, 9103-9116.
202. Neufeld-Cohen A., Tsoory M.M., Evans A.K., Getselter D., Gil S., Lowry C.A., Vale W.W., Chen A. A triple urocortin knockout mouse model reveals an essential role for urocortins in stress recovery. Proc Natl Acad Sci USA. 1902, 107:0-5.
203. Holsboer F., Ising M. Central CRH system in depression and anxiety-evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol. 2008, 583:350-357.
204. Binder EB, NemeroffCB. The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol Psychiatry. 15, 574-88.
205. NemeroffC.B., Widerlov E., Bissette G., Walleus H., Karlsson I., Eklund K., Kilts C.D., Loosen P.T., Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science. 1984, 226:1342-1344.
206. Banki C.M., Bissette G., Arato M., O'Connor L., NemeroffC.B. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry. 1987, 144:873-877.
207. Hartline K.M., Owens M.J., NemeroffC.B. Postmortem and cerebrospinal fluid studies of corticotropin-releasing factor in humans. Ann NY Acad Sci. 1996, 780:96-105.
208. Arato M., Banki C.M., Bissette G., NemeroffC.B. Elevated CSF CRF in suicide victims. Biol Psychiatry. 1989, 25:355-359.
209. NemeroffC.B., Bissette G., Akil H., Fink M. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin. Br J Psychiatry. 1991, 158:59-63.
210. De Bellis M.D., Gold P.W., Geracioti T.D., Listwak S.J., Kling M.A. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry. 1993, 150:656-657.
211. Veith R.C., Lewis N., Langohr J.I., Murburg M.M., Ashleigh E.A., Castillo S., Peskind E.R., Pascualy M., Bissette G., NemeroffC.B., et al. Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Psychiatry Res. 1993, 46:1-8.
212. Heuser I., Bissette G., Dettling M., Schweiger U., Gotthardt U., Schmider J., Lammers C.H., NemeroffC.B., Holsboer F. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. Depress Anxiety. 1998, 8:71-79.
213. Banki C.M., Karmacsi L., Bissette G., NemeroffC.B. CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. Eur Neuropsychopharmacol. 1992, 2:107-113.
214. Gold P.W., Chrousos G.P. Clinical studies with corticotropin releasing factor: implications for the diagnosis and pathophysiology of depression, Cushing's disease, and adrenal insufficiency. Psychoneuroendocrinology. 1985, 10:401-419.
215. Holsboer F., Gerken A., Stalla G.K., Muller O.A. Blunted aldosterone and ACTH release after human CRH administration in depressed patients. Am J Psychiatry. 1987, 144:229-231.
216. Amsterdam J.D., Maislin G., Winokur A., Kling M., Gold P. Pituitary and adrenocortical responses to the ovine corticotropin releasing hormone in depressed patients and healthy volunteers. Arch Gen Psychiatry. 1987, 44:775-781.
217. Merali Z., Du L., Hrdina P., Palkovits M., Faludi G., Poulter M.O., Anisman H. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci. 2004, 24:1478-1485.
218. NemeroffC.B., Owens M.J., Bissette G., Andorn A.C., Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry. 1988, 45:577-579.
219. Austin M.C., Janosky J.E., Murphy H.A. Increased corticotropin-releasing hormone immunoreactivity in monoamine-containing pontine nuclei of depressed suicide men. Mol Psychiatry. 2003, 8:324-332.
220. Merali Z., Kent P., Du L., Hrdina P., Palkovits M., Faludi G., Poulter M.O., Bedard T., Anisman H. Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. Biol Psychiatry. 2006, 59:594-602.
221. Raadsheer F.C., Hoogendijk W.J., Stam F.C., Tilders F.J., Swaab D.F. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology. 1994, 60:436-444.
222. Bissette G., Klimek V., Pan J., Stockmeier C., Ordway G. Elevated concentrations of CRF in the locus coeruleus of depressed subjects. Neuropsychopharmacology. 2003, 28:1328-1335.
223. Wang S.S., Kamphuis W., Huitinga I., Zhou J.N., Swaab D.F. Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances. Mol Psychiatry. 2008, 13:786-799. 741.
224. Kozicz T., Tilburg-Ouwens D., Faludi G., Palkovits M., Roubos E. Gender-related urocortin 1 and brain-derived neurotrophic factor expression in the adult human midbrain of suicide victims with major depression. Neuroscience. 2008, 152:1015-1023.
225. Kang H.J., Adams D.H., Simen A., Simen B.B., Rajkowska G., Stockmeier C.A., Overholser J.C., Meltzer H.Y., Jurjus G.J., Konick L.C., Newton S.S., Duman R.S. Gene expression profiling in postmortem prefrontal cortex of major depressive disorder. J Neurosci. 2007, 27:13329-13340.
226. Binder EB, Owens MJ, Liu W, Deveau TC, Rush AJ, Trivedi MH, Fava M, Bradley B, Ressler KJ, NemeroffCB. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry. 67, 369-379.
227. Wasserman D, Wasserman J, Sokolowski M. Genetics of HPA-axis, depression and suicidality. Eur Psychiatry. 25, 278-280.
228. Licinio J., O'Kirwan F., Irizarry K., Merriman B., Thakur S., Jepson R., Lake S., Tantisira K.G., Weiss S.T., Wong M.L. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry. 2004, 9:1075-1082.
229. Liu Z., Zhu F., Wang G., Xiao Z., Tang J., Liu W., Wang H., Liu H., Wang X., Wu Y., Cao Z., Li W. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett. 2007, 414:155-158.
230. Liu Z., Zhu F., Wang G., Xiao Z., Wang H., Tang J., Wang X., Qiu D., Liu W., Cao Z., Li W. Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression. Neurosci Lett. 2006, 404:358-362.
231. Wasserman D., Sokolowski M., Rozanov V., Wasserman J. The CRHR1 gene: a marker for suicidality in depressed males exposed to low stress. Genes Brain Behav. 2008, 7:14-19.
232. Wasserman D., Wasserman J., Rozanov V., Sokolowski M. Depression in suicidal males: genetic risk variants in the CRHR1 gene. Genes Brain Behav. 2009, 8:72-79.
233. Papiol S., Arias B., Gasto C., Gutierrez B., Catalan R., Fananas L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord. 2007, 104:83-90.
234. Bradley R.G., Binder E.B., Epstein M.P., Tang Y., Nair H.P., Liu W., Gillespie C.F., Berg T., Evces M., Newport D.J., Stowe Z.N., Heim C.M., NemeroffC.B., Schwartz A., Cubells J.F., Ressler K.J. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry. 2008, 65:190-200.
235. De Luca V., Tharmalingam S., Kennedy J.L. Association study between the corticotropin-releasing hormone receptor 2 gene and suicidality in bipolar disorder. Eur Psychiatry. 2007, 22:282-287.
236. Held K., Kunzel H., Ising M., Schmid D.A., Zobel A., Murck H., Holsboer F., Steiger A. Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. J Psychiatr Res. 2004, 38:129-136.
237. Kunzel H.E., Zobel A.W., Nickel T., Ackl N., Uhr M., Sonntag A., Ising M., Holsboer F. Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J Psychiatr Res. 2003, 37:525-533.
238. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Sonntag A., Ising M., Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res. 2000, 34:171-181.
239. Mathew S.J., Price R.B., Charney D.S. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am J Med Genet C Semin Med Genet. 2008, 148C:89-98.
240. Yehuda R., Giller E.L., Southwick S.M., Lowy M.T., Mason J.W. Hypothalamic-pituitary-adrenal dysfunction in posttraumatic stress disorder. Biol Psychiatry. 1991, 30:1031-1048.
241. de Kloet C.S., Vermetten E., Geuze E., Kavelaars A., Heijnen C.J., Westenberg H.G. Assessment of HPA-axis function in posttraumatic stress disorder: pharmacological and non-pharmacological challenge tests, a review. J Psychiatr Res. 2006, 40:550-567.
242. Erhardt A., Ising M., Unschuld P.G., Kern N., Lucae S., Putz B., Uhr M., Binder E.B., Holsboer F., Keck M.E. Regulation of the hypothalamic-pituitary-adrenocortical system in patients with panic disorder. Neuropsychopharmacology. 2006, 31:2515-2522.
243. Schreiber W., Lauer C.J., Krumrey K., Holsboer F., Krieg J.C. Dysregulation of the hypothalamic-pituitary-adrenocortical system in panic disorder. Neuropsychopharmacology. 1996, 15:7-15.
244. Bremner J.D., Licinio J., Darnell A., Krystal J.H., Owens M.J., Southwick S.M., NemeroffC.B., Charney D.S. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry. 1997, 154:624-629.
245. Baker D.G., West S.A., Nicholson W.E., Ekhator N.N., Kasckow J.W., Hill K.K., Bruce A.B., Orth D.N., Geracioti T.D. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry. 1999, 156:585-588.
246. Sautter F.J., Bissette G., Wiley J., Manguno-Mire G., Schoenbachler B., Myers L., Johnson J.E., Cerbone A., Malaspina D. Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. Biol Psychiatry. 2003, 54:1382-1388.
247. Banki C.M., Karmacsi L., Bissette G., NemeroffC.B. Cerebrospinal fluid neuropeptides in mood disorder and dementia. J Affect Disord. 1992, 25:39-45.
248. Fossey M.D., Lydiard R.B., Ballenger J.C., Laraia M.T., Bissette G., NemeroffC.B. Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biol Psychiatry. 1996, 39:703-707.
249. Jolkkonen J., Lepola U., Bissette G., NemeroffC., Riekkinen P. CSF corticotropin-releasing factor is not affected in panic disorder. Biol Psychiatry. 1993, 33:136-138.
250. Chappell P., Leckman J., Goodman W., Bissette G., Pauls D., Anderson G., Riddle M., Scahill L., McDougle C., Cohen D. Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls. Biol Psychiatry. 1996, 39:776-783.
251. Smoller J.W., Rosenbaum J.F., Biederman J., Kennedy J., Dai D., Racette S.R., Laird N.M., Kagan J., Snidman N., Hirshfeld-Becker D., Tsuang M.T., Sklar P.B., Slaugenhaupt S.A. Association of a genetic marker at the corticotropin-releasing hormone locus with behavioral inhibition. Biol Psychiatry. 2003, 54:1376-1381.
252. Smoller J.W., Yamaki L.H., Fagerness J.A., Biederman J., Racette S., Laird N.M., Kagan J., Snidman N., Faraone S.V., Hirshfeld-Becker D., Tsuang M.T., Slaugenhaupt S.A., Rosenbaum J.F., Sklar P.B. The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder. Biol Psychiatry. 2005, 57:1485-1492.
253. Keck M.E., Kern N., Erhardt A., Unschuld P.G., Ising M., Salyakina D., Muller M.B., Knorr C.C., Lieb R., HohoffC., Krakowitzky P., Maier W., Bandelow B., Fritze J., Deckert J., Holsboer F., Muller-Myhsok B., Binder E.B. Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. Am J Med Genet B Neuropsychiatr Genet. 2008, 147B:1196-1204.
254. Cryan J.F., Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov. 2005, 4:775-790.
255. Wong M.L., Licinio J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug. Discov. 2004, 3:136-151.
256. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature. 2008, 455:894-902.
257. Francis D.D., Szegda K., Campbell G., Martin W.D., Insel T.R. Epigenetic sources of behavioral differences in mice. Nat Neurosci. 2003, 6:445-446.
258. McEwen B.S. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 2007, 87:873-904.
259. Ulrich-Lai Y.M., Herman J.P. Neural regulation of endocrine and autonomic stress responses. Nat Rev Neurosci. 2009, 10:397-409.
260. Lupien S.J., McEwen B.S., Gunnar M.R., Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci. 2009, 10:434-445.
261. McEwen BS. Stress, sex, and neural adaptation to a changing environment: mechanisms of neuronal remodeling. Ann NY Acad Sci. 1204 Suppl, E38-59.
262. Holsboer F, Ising M. Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol. 61, 81-109, C1-11.
263. Bale T.L. Sensitivity to stress: dysregulation of CRF pathways and disease development. Horm Behav. 2005, 48:1-10.
264. Zorrilla E.P., Koob G.F. The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig Drugs. 2004, 13:799-828.